STAT | Reporting from the frontiers of health and medicine Follow STAT+: Scholar Rock wins FDA approval for first drug to target SMA muscle loss A late-stage clinical trial found that, when combined with an SMN2-targeting drug, Isembyld caused young patients’ motor skills to improve after a year. https://www.statnews.com/2026/09/11/scholar-rock-spinal-muscular-atrophy-isembyld-clinical-trial-fda-approval/ statnews.com
